| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
90 |
| Employees |
131 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-71 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Allakos Inc. is a biopharmaceutical company based in California that specializes in the development of therapeutic antibodies for the treatment of various immune-mediated diseases. The company was founded in 2012 by Nessa Carion and Dr. Robert Alexander, and went public in 2018 (NASDAQ: ALLK).
Allakos has a unique focus on eosinophilic and mast cell-related diseases, which are conditions that result from the dysfunction of certain types of immune cells. These diseases can be chronic and debilitating, affecting multiple organ systems and leading to a host of complications.
Allakos has several drug candidates in its pipeline, with its lead product, AK002, being tested clinically for several indications, including eosinophilic gastritis and urticaria, chronic rhinosinusitis with nasal polyps, and indolent systemic mastocytosis. AK002 is an antibody that targets the cell surface receptor Siglec-8, which is expressed on eosinophils and mast cells. By binding to Siglec-8, AK002 is thought to reduce the activation and proliferation of these cells, thereby reducing inflammation and symptoms associated with the target diseases.
In addition to AK002, Allakos is also developing two other drug candidates: AK001, which targets a different receptor on mast cells, and AK003, which targets a cytokine called IL-33 that is involved in the activation of mast cells and other immune cells.
Allakos has a robust research program, with a strong focus on identifying new drug targets and developing novel therapies for unmet medical needs. The company has collaborations with academic and industry partners, including the National Institutes of Health, to leverage their expertise and resources.
Overall, Allakos is a dynamic and growing biopharmaceutical company that is making strides in developing new treatments for immune-mediated diseases. Its innovative approach and promising drug candidates have garnered attention from investors, clinicians, and patients alike.
Company Address: 149 Commonwealth Dr Menlo Park 94025 CA
Company Phone Number: 597-5002 Stock Exchange / Ticker: NASDAQ ALLK
|
%
4.62% 